Related Experiment Videos
The in vitro activity of ceftazidime against a multi-resistant serotype 12 Pseudomonas aeruginosa
Abstract:
Highly resistant isolates of Pseudomonas aeruginosa serotype 12 accounted for 42.2% of the pseudomonads isolated from patients in a 600-bed hospital over a period of 18 months. In vitro studies showed that this organism was resistant to tobramycin, gentamicin, apalcillin, piperacillin, azlocillin, ticarcillin, cefotaxime and cefsulodin. All serotype 12 isolates were completely sensitive to ceftazidime. Its geometric mean MIC was 3.4 mg/l. This new cephalosporin seems promising for the treatment of patients infected with pseudomonas, especially when a resistant strain such as serotype 12 is involved.
Insights
Highly resistant Pseudomonas aeruginosa serotype 12 strains were common in hospitals. This study found ceftazidime effective against these difficult-to-treat infections, offering a promising treatment option.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa is a significant nosocomial pathogen.
- Highly resistant strains, particularly serotype 12, pose a clinical challenge.
- Prevalence of resistant P. aeruginosa serotype 12 was assessed in a hospital setting.
Purpose of the Study:
- To determine the prevalence of P. aeruginosa serotype 12.
- To evaluate the in vitro susceptibility of P. aeruginosa serotype 12 to various antibiotics.
- To assess the efficacy of ceftazidime against resistant P. aeruginosa serotype 12.
Main Methods:
- Isolation and serotyping of Pseudomonas aeruginosa from patient samples over 18 months.
- In vitro antimicrobial susceptibility testing using standard microbiological methods.
- Determination of minimum inhibitory concentration (MIC) for ceftazidime.
Main Results:
- Highly resistant P. aeruginosa serotype 12 constituted 42.2% of isolates.
- Isolates showed resistance to multiple antibiotics including gentamicin, tobramycin, and several penicillins and cephalosporins.
- All serotype 12 isolates were susceptible to ceftazidime, with a geometric mean MIC of 3.4 mg/l.
Conclusions:
- P. aeruginosa serotype 12 is a prevalent and highly resistant strain in hospital environments.
- Ceftazidime demonstrates significant in vitro activity against these resistant isolates.
- Ceftazidime is a promising therapeutic option for infections caused by P. aeruginosa serotype 12.